Top Markets
Coin of the day
Evgen Pharma plc Evgen Pharma plc

Evgen Pharma plc

EVG
Rangering i aksjer #38016
Evgen Pharma plc, a UK-based pharmaceutical company founded in 2014, operates... Evgen Pharma plc, a UK-based pharmaceutical company founded in 2014, operates at the clinical development stage, concentrating on the creation of sulforaphane-based medications. Its mission is to combat various cancers and inflammatory conditions. The firm utilizes its proprietary Sulforadex technology, which is engineered to stabilize sulforaphane, in its product development. SFX-01 stands as their principal drug candidate, currently in Phase II clinical trials for metastatic breast cancer and Phase Ib/IIa trials for glioblastoma. Furthermore, SFX-01 is being investigated in preclinical stages for haematological malignancies and analogous disorders. The company also offers out-licensing services for its innovative technology.
Aksjekurs
$0.00953895
Sist synkronisert: 2024-05-22
Markedsverdi
$1.28M
Endring (1 dag)
0.06%
Endring (1 år)
0.00%
Land
GB
Handel Evgen Pharma plc (EVG)

Kategori

P/B-forhold for Evgen Pharma plc (EVG)
P/B-forhold per 2026 TTM: 0
Ifølge Evgen Pharma plc sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for Evgen Pharma plc fra 2026 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
Ikke nok data for de angitte datoene.
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE